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Abstract The adenosine antagonist 7-methylxanthine (7-
mx) works against myopia in animal models. In a clinical
trial, 68 myopic children (mean age 11.3 years) received
either placebo or 7-mx tablets for 12 months. All
participants subsequently received 7-mx for another
12 months, after which treatment was stopped. Axial length
was measured with Zeiss IOL-Master and cycloplegic
refraction with Nikon Retinomax at −6, 0, 12, 24, and
36 months. Axial growth was reduced among children
treated with 7-mx for 24 months compared with those only
treated for the last 12 months. Myopia progression and
axial eye growth slowed down in periods with 7-mx
treatment, but when the treatment was stopped, both
myopia progression and axial eye growth continued with
invariable speed. The results indicate that 7-mx reduces eye
elongation and myopia progression in childhood myopia.
The treatment is safe and without side effects and may be
continued until 18–20 years of age when myopia progres-
sion normally stops.
Keywords 7-methylxanthine.
Adenosinereceptorantagonist.Myopia.Clinicaltrial
Introduction
Normally, the axial length of the human eye increases
from 17 mm at birth to 24 mm at 14 years of age. From
an initial hypermetropia the refraction gradually changes
toward emmetropia. It has been hypothesized that a
growth-control mechanism exists, which can either
accelerate or slow down axial growth in response to
defocusing of the retinal image during the period of
normal eye growth. Results from experimental myopia in
mammals suggest that this mechanism works by regulat-
ing the scleral extensibility through complex changes in
the synthesis and degradation of extracellular matrix
components [1–3].
In myopic children an excessive eye elongation is typically
seenfromage6yearsuntil20years.Theaxiallengthwillthen
be in the range of 24–28 mm. Until the age of 14 years, the
increase in myopia is approximately linear [4], after which a
slow deceleration is seen [5]. With maturity, an increase in
collagen cross-linking occurs [6], which probably explains
the gradual stabilization of myopia. The myopic eye differs
in shape from normal eyes, because the increase in length
(0.35 mm per diopter) is greater than the increase in height
(0.19 mm per diopter) and width (0.1 mm per diopter),
resulting in the characteristic “egg-shape” of highly myopic
eyes [7].
With increasing axial length there is an increased risk of
potentially blinding complications later in life, such as
retinal detachment, macular degeneration, or glaucoma.
About 23% of all cases of retinal detachment occur in eyes
with myopia of more than −6 dioptres [8]. This underlines
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prevent excessive axial elongation.
There is today no treatment that efficiently and without
side effects controls the progression of myopia [9].
Topically applied muscarine antagonists, like the non-
selective antagonist atropine, and the M1 selective antag-
onist pirenzepine have been shown to reduce myopia
progression and axial eye growth [10–12]. The mechanism
of action of atropine and pirenzepine has not been
established, but it is assumed that it is independent of their
action on accommodation, and that it may depend on
receptors in the retina or the sclera [13]. Reduced
accommodation and dilation of the pupil, however, remain
a problem both with atropine and to a lesser degree with
pirenzepine.
The biomechanical properties of sclera are determined
by the contents and organization of proteoglycans and
collagen [14]. Collagen accounts for about 80% of the dry
weight of sclera [15]. It is known that plastic deformation
(creep) of tissues is directly related to the proportion of
small diameter fibrils [16]. The diameter of the collagen
fibrils in sclera from myopic eyes is reduced compared to
normal eyes, as are the contents of collagen and glyco-
saminoglycans [17].
Experimental myopia in mammals is accompanied by a
decrease in the scleral content of proteoglycans and collagen
[18], with reverse changes taking place during recovery [19].
In mammalian models of high myopia, a thinning of the
posterior sclera and an increased number of small diameter
collagen fibrils in posterior sclera is found [20, 21].
Treatment of young rabbits with a metabolite of caffeine
and theobromine, 7-methylxanthine (7-mx), increases the
thickness of the posterior sclera, increases the content of
collagen-related amino acids in posterior sclera, and at the
same time increases the diameter of the collagen fibrils in
the posterior sclera [22]. Recently, 7-mx has been shown to
reduce the amount of myopia and eye elongation induced
by form deprivation in guinea pigs and to counteract the
thinning of posterior sclera and of collagen fibrils induced
by form deprivation [23].
Theobromine and its metabolite, 7-mx, both have very low
toxicity[24, 25] and no carcinogenic effects [26]. The aim of
this study was to test whether 7-mx is useful against axial
elongation and myopia progression in childhood myopia.
Subjects and methods
Participants
One hundred seven children, aged 8–13 years, with a
minimum myopia of −0.75 diopters (cycloplegic) in one
eye were screened using two subject visits with an average
interval of 6 months. Eighty-three were found to have an
average axial growth rate of 0.075–0.39 mm per 6 months,
and were enrolled in the study. The low cut-off was chosen
in order to exclude children with a normal or close to
normal axial growth rate. The high cut-off was chosen in
order to exclude atypical cases with an extremely fast
progression. The normal axial growth rate in children of
this age-group is around 0.05 mm per 6 months [27].
All participants were Danish. Children using soft contact
lenses were accepted. All children used single vision lenses.
The degree of under-correction was not assessed, but the
parents were encouraged to have the children’s correction
adjusted at regular intervals.
The study followed the tenets of the Declaration of
Helsinki. Informed consent was obtained from the partic-
ipants and their parents. Approval was obtained from the
Danish Medicines Agency and the Ethics Committee for the
municipality of Copenhagen and Frederiksberg. The trial
was registered at www.clinicaltrials.gov, Reg.NCT00263471.
Intervention
During a 12-months placebo-controlled trial, participants
received one tablet every morning. The tablets had a
diameter of 12 mm and a thickness of 3 mm. Active tablets
contained 400 mg 7-mx, placebo tablets only standard
filling and binding substances.
Peak serum concentration after an oral dose of 400 mg
7-mx in adults is around 20 µmol/l with a half-life of
200 min (unpublished results, SM Ribel-Madsen & K Trier,
2004). In the rabbit experiment mentioned above [22], peak
serum level of 7-mx was around 70 µmol/l and half-life
around 1 h.
The 7-mx substance was synthesized by Sigma-Aldrich
Co. (Fluka works, Buchs, Switzerland). The tablets were
manufactured and packed in a pharmacy certified for
pharmaceutical production (Glostrup, Denmark). Partici-
pants were asked to bring unused tablets at the end of the
follow-up period and the remaining tablets were counted.
Outcome measures
The primary outcome measure was axial growth rate.
Secondary outcome measure was myopia progression.
The axial length was monitored with non-contact, partial
coherence interferometer (Zeiss IOL-Master) [28]. The
refraction was measured with an autorefractor (Retinomax,
Nikon) 30 min after one drop of 1% cyclopentolate in each
eye. In case of astigmatism, half of the astigmatism was
added to the sphere. The same Retinomax autorefractor and
IOL-Master was used throughout the trial. Measurement
stability was confirmed by means of test eyes. Outcome
measures were taken four times and the average calculated.
86 j ocul biol dis inform (2008) 1:85–93Weight was measured at base-line, and weight, height,
blood pressure, heart rateatthe endof the trial, andparticipants
were questioned specifically for CNS, gastrointestinal or
cardiopulmonal symptoms.
Sample size
From a pilot trial, a standard deviation of 0.063 mm on
axial growth per year was found. The smallest difference in
mean value of axial growth not to be overlooked was set to
0.050 mm. With an accepted risk of type I error of 5% and
of type II error of 20%, it was calculated that the number of
participants needed in each group was 24.
Randomization
For the 12-month placebo-controlled trial, participants were
randomized in a 1:1 ratio to receive 7-mx or placebo. The
allocation sequence was generated in the pharmacy and
sealed and numbered containers consecutively handed out
to the participants. Outcomes were assessed unaware of
group assignment at Trier Research Laboratories. No
participants or investigators became unmasked during the
first 12 months of the trial.
Statistical methods
The distribution of demographic data did not deviate substan-
tially from the normal and variances were homogeneous,
hence parametric tests were used. For all data on the state and
development of myopia was calculated the average of data
from each subject’s right and left eye, and these average data
were subjected to significance tests. The significance of
differences between mean values referring to the respective
treatment groups was tested with Mann–Whitney test, because
of inequality of variances of some of the variables. The
significance of differences in axial length or myopia progres-
sion rates between periods within the same individual was
tested with paired Student’s t test. Correlations were analyzed
with Pearson’s test and proportions with Fisher’s exact test.
24-months follow-up
After completing the 12-month placebo-controlled trial,
children from both the placebo and the 7-mx group were
given the option of continued treatment with 7-mx 400 mg
either once or twice per day for another 12 months.
36-months follow-up
After completing 24-month follow-up, all participants
discontinued treatment with 7-mx, and axial growth and
myopia progression was followed for another year by
measurement at the end of the total of 36 months’
follow-up.
Results
12-month placebo-controlled trial
The 12-month placebo-controlled trial was completed by 77
children.
The reason for not completing was in no case stated as
side effects. Compliance among those completing the 12-
month placebo-controlled trial was 89% in the 7-mx group
versus 92% in the placebo group. No differences were
found as to weight, height, blood pressure, and heart rate.
No subjective side effects were reported.
Axial growth rate during the 12-month placebo treatment
period was found to be proportional to base-line level (p<
0.01, Fig. 1). To ensure comparability between the 7-mx
and the placebo group, data were therefore compared within
two stratification layers, one with a base-line axial growth
rate of 0.075–0.190 mm per 6 months, including 19 treated
with 7-mx and 27 treated with placebo, and the other with a
base-line axial growth rate of 0.200–0.390 mm per
6 months, including 16 treated with 7-mx and 15 treated
with placebo.
Tables 1 and 2 show axial growth, myopia progression,
and change in corneal curvature in the two stratification
layers. In both, axial growth was reduced in the 7-mx group
compared with the placebo group. The difference was
−0.055 mm per year (95% Cl −0.114 and +0.005 mm per
year) for children with a moderate base-line axial growth
rate (p=0.073), and −0.031 mm per year (95% Cl −0.150
Fig. 1 Correlation between axial length growth-rate during the 12-
months placebo controlled trial and the observation period before
intervention, shown as mean values for right and left eye in each of
the participants in the placebo group (p<0.01)
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88 j ocul biol dis inform (2008) 1:85–93and +0.087 mm per year) for children with a high base-line
growth rate (p=0.593).
Also the myopia progression was lower in the 7-mx group
ofbothstratificationlayers,withadifferenceof−0.108diopters
per year (95% Cl −0.288 and +0.070 diopters per year) (p=
0.227) and −0.091 diopters per year (95% Cl −0.424 and
+0.243 diopters per year)(p=0.582), respectively.
24-month follow-up
The 24-month follow-up period was completed by 68
children. The average daily dose of 7-mx taken by each child
during the last 12 months of the follow-up ranged from 40–
706 mg per day, average 444 mg per day. No subjective side
effects were reported.
Axial growth in children with a moderate base-line axial
growth rate (n=40) treated for 24 months with 7-mx was
0.329 mm (SD 0.143 mm) compared with 0.427 mm (SD
0.193 mm) in the group treated with placebo for the first
12 months and with 7-mx for the last 12 months (p=0.048)
(Fig. 2). The corresponding axial growth for children with a
high base-line axial growth (n=28) was 0.547 mm (SD
0.212 mm) for the 7-mx group, and 0.584 mm (SD
0.193 mm) for the placebo/7-mx group (p=0.667) (Fig. 3).
Myopia progression in children with a moderate base-
line axial growth rate (n=40) treated for 24 months with 7-
mx was 0.627 diopters (SD 0.329 diopters) compared with
0.844 diopters (SD 0.450 diopters) in the group treated with
placebo for the first 12 months and with 7-mx for the last
12 months (p=0.141) (Fig. 4). The corresponding myopia
progression for children with a high base-line axial growth
(n=28) was 1.131 diopters (SD 0.443 diopters) for the 7-
mx group, and 1.010 diopters (SD 0.549 diopters) for the
placebo/7-mx group (p=0.667) (Fig. 5).
Percentage myopia stabilization in the period 12–
24 months (defined as less than 0.25 diopters myopia
progression during the 12 months) is shown in Table 3.
Among children treated for the whole 24-month period with
7-mx, 59% of children with a moderate axial growth rate at
base-line, and 20% of children with a high axial growth rate
at base-line were stable.
36-month follow-up
Sixty-one children completed 36-month follow-up. In both
the group treated with 7-mx 0–24 months (n=28) and the
group treated with placebo 0–12 months and 7-mx 12–
24 months (n=33), axial growth rate in the first as well as the
second year of treatment was significantly lower compared
with the precedent period (p<0.00001/p=0.001, first year
and p=0.006/p=0.001, second year) (Fig. 6a–b). The
myopia progression rate, on the other hand, only slowed
down in periods with 7-mx treatment (p<0.0005/p=0.098,
first year and p=0.013/p=0.01, second year) (Fig. 6c–d).
However, in both groups, axial growth rate (p=0.533/p=
0.179) and myopia progression rate (p=0.162/p=0.138)after
discontinuation of the treatment (third year) did not differ
significantly from the precedent period (Fig. 6a–d).
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In this study, base-line axial growth rate was taken into
consideration when comparing inter-group differences in
axial growth. The rate of myopia progression is believed to
be the most important variate as regards base-line compara-
bility [29]. The finding of a significant correlation between
axial growth at base-line and axial growth in the first
12 months of the intervention period supports the importance
of using the axial growth rate as one of the inclusion criteria
in myopia studies. Frequency of contact lens wear was close
to equal in the 7-mx group and the placebo group (17%
versus 19% during the 12-months trial). Contact lens wear
does not seem to affect the growth of the vitreous chamber
significantly [30].
The degree of under-correction in the participants was
not recorded in this trial, and could therefore theoretically
be a confounding factor. One study found that under-
correction enhances myopia progression [31], while another
found no effect [32]. It is not known whether the axial
growth rate is affected by under-correction.
At 12 months, the lowest axial growth in both
stratification layers was found in the 7-mx groups, but the
differences were not significant.
At 24 months, however, a significantly lower axial growth
was found in children with a moderate base-line axial growth
rate treated for all 24 months with 7-mx compared with those
treated with placebo for the first 12 months and 7-mx for the
last 12 months (difference 0.098 mm), whereas the differ-
ence among children with a high base-line axial growth rate
(0.037 mm) was non-significant.
Children with a high base-line axial growth rate (0.200–
0.390 mm per 6 months) have a myopia progression of up
to 2 diopters per year. Such severely progressing myopia is
frequently linked to specific genetic abnormalities, and may
therefore represent a sub-group, possibly more refractory to
treatment than the majority of myopes.
Nevertheless, in the second year of the intervention
period, average axial growth among children with a high
base-line axial growth rate treated for all 24 months with 7-
mx, was reduced to 0.22 mm per year from an initial
0.52 mm per year at base-line. This is lower than the
expected average axial growth rate of 0.25 mm per year for
age-matched Danish myopes, including low-, moderate-,
and high-progressors [33]. The corresponding myopia
progression rate in the second year of the intervention
period among children with a high base-line axial growth
rate treated for all 24 months with 7-mx was reduced to
0.49 diopters per year from 1.20 diopters per year at base-
line. The expected average myopia progression rate for age-
matched Danish myopes, including low-, moderate-, and
high-progressors is 0.48 diopters per year [33]. For children
with a moderate axial growth rate at base-line (0.075–
0.190 mm per 6 months), treated for all 24 months with 7-
mx, axial growth rate was reduced to 0.14 mm per year in
the second year of treatment from 0.27 mm per year at
base-line, and the myopia progression rate to 0.23 diopters
per year in the second year of treatment from 0.52 diopters
per year at base-line. Thus, in comparison to the average of
age-matched Danish myopes, including low-, moderate-,
and high-progressors [33], both axial growth and myopia
progression was reduced by around 50% in the second year
of treatment with 7-mx.
In an unselected material of myopes, the percent with
stable myopia increased with age from 14% for 12-year-
olds to 63% for 18-year-olds [34]. In comparison, our
finding of a markedly higher percentage of stable myopia
(59% and 21%, moderate and high base-line axial growth
rate respectively) in the second year of treatment, further
supports that treatment with 7-mx stabilizes myopia.
In the age interval 11–14 years, myopia progression and
axial elongation is close to linear [14]. A decrease in both
myopia progression rate and axial elongation rate during
both the first and the second year of treatment with 7-mx is
therefore unexpected. The absence of a further reduction of
Table 3 Myopia stabilization in the period 12–24 months
Base-line axial
growth 0.075–
0.190 mm per
6 months
Base–line axial
growth 0.200–
0.390 mm per
6 months
Placebo 12 months/
7-methylxanthine
12 months
35% 21%
7-methylxanthine
24 months
59% 21%
p value 0.2 1.0
-0,8
-0,6
-0,4
-0,2
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Fig. 5 Myopia progression in children with a base-line axial growth
rate of 0.200–0.390 mm per 6 months (n=28). In the period 12–
24 months, both groups received 7-methylxanthine. The difference at
24 months was 0.121 diopters (95% Cl −0.267 and 0.508 diopters, p=
0.541)
90 j ocul biol dis inform (2008) 1:85–93myopia progression and axial elongation in the third year
coincides with the discontinuation of treatment and is
consistent with the treatment being efficient.
Methylxanthines in non-toxic doses block adenosine
receptors (ADOR) competitively. Adenosine in the concen-
trations found under physiological conditions activates
primarily A1 and A2A adenosine receptors (ADORA1
and ADORA2A) on the cell surface. ADORA1s are widely
distributed in the CNS, whereas ADORA2As are found
mainly in the dopamine-rich regions of the brain [35].
Adenosine has a general homeostatic role in the
regulation of cell metabolism, but also a specific neuro-
modulatory role with ADORA1s having an inhibitory role
and ADORA2As having a facilitatory role in the release
of neurotransmitters such as dopamine, noradrenalin,
acetylcholine, glutamate, and serotonin [36]. ADORA1s
and ADORA2As have been localized in the ciliary body
and the retina and ADORA2As in the retinal pigment
epithelium of adult rats [37] and humans (unpublished
results, Zhongshan Ophthalmic Center). Both ADORA1s
and ADORA2As are expressed in human scleral fibroblasts
[38].
Experimental myopia in animals has been linked to
changes in retinal dopamine and acetylcholine neurotrans-
mission [39–44]. Both of these neurotransmitters are
modulated by ADORs [45–50]. The mechanism by which
7-mx affects eye elongation and myopia progression could
therefore theoretically involve modulation of muscarinic
acetycholine or dopamine receptors. On the other hand, it is
also possible that ADORs are directly involved in the
control of eye growth. Because of receptor adaptation, the
effects related to blocking of ADOR1s are attenuated
during chronic treatment with non-selective ADOR antag-
onists like 7-mx, whereas effects related to blocking of
ADORA2As are unchanged [51–53].
Adenosine liberated from the retina is believed to
activate ADORA2s on the retinal pigment epithelium and
augment the standing potential (SP) [54]. The effect on the
SP might therefore give us a measure of the potency of a
specific methylxanthine as a blocker of adenosine recep-
tors. The receptor affinity of 7-mx is three to five times
higher than theobromine [55]. Correspondingly, the light-
rise of SP in humans is more reduced by 7-mx than by
theobromine (unpublished results, K Trier, 2004). Interest-
ingly, high ametropia in children is associated with retinal
electrophysiological abnormalities, a finding consistent
with the hypothesis that the retina is involved in the
process of emmetropization [56].
In conclusion, systemic treatment with 7-mx appears to
be efficient in retarding axial elongation and myopia
progression among myopic children. The treatment is safe
and without side effects, and may be continued until 18–
20 years of age, when age-related cross-linking of collagen
prevents further elongation of the eye.
Fig. 6 a, b Axial growth rate before trial, during treatment with 7-mx
or placebo in the first year, during treatment with 7-mx in the second
year, and after discontinuation of treatment. In the first and second
year, axial growth rate is significantly lower than in the precedent
period, but in the third year, after discontinuation of treatment, axial
growth rate is not different from the precedent year. c, d Myopia
progression rate in the same periods. The myopia progression rate is
significantly reduced compared with the precedent period during
treatment with 7-mx, but unchanged in periods with placebo treatment
or no treatment
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